Join
Live feed
·
PRReleasevia Quantisnow
Apogee Therapeutics Inc. logo

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

ByQuantisnow·Wall Street's wire, on your screen.
APGE· Apogee Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APGE (Apogee Therapeutics Inc.) and more on Quantisnow.